Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00621504 · ClinicalTrials.gov registry record · Phase 3

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

A Phase 3 study, sponsored by Forest Laboratories.

Completed
Registry status
Phase 3
Development phase
606
Enrollment target

NCT00621504 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 606 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00621504, a Phase 3 study, has completed, sponsored by Forest Laboratories.

COMPLETED
Registry status
Phase 3
Development phase
606 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

Interventions

  • DRUG Placebo
  • DRUG Clarithromycin
  • DRUG Ceftaroline fosamil for Injection
  • DRUG IV Ceftriaxone

Trial Details

FieldValue
Enrollment Target 606 participants
Start Date 2008-01
Est. Completion 2009-06
Phase Phase 3

Sponsor

Forest Laboratories

145 total trials

What the Registry Record Tells You About NCT00621504

The ClinicalTrials.gov registry entry for NCT00621504 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 606 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT00621504 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00621504 about?

NCT00621504 is a clinical study titled "Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia". The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

What is the current status of trial NCT00621504?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2008-01. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00621504?

The interventions under investigation include: Placebo (DRUG), Clarithromycin (DRUG), Ceftaroline fosamil for Injection (DRUG), IV Ceftriaxone (DRUG).

Who is sponsoring clinical trial NCT00621504?

This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.